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Human lysine-specific demethylase (LSD1) is a chromatin-
modifying enzyme that specifically removesmethyl groups from
mono- and dimethylated Lys4 of histoneH3 (H3-K4).We used a
combination of in vivo and in vitro experiments to characterize
the substrate specificity and recognition by LSD1. Biochemical
assays on histone peptides show that essentially all epigenetic
modifications on the 21 N-terminal amino acids of histone H3
cause a significant reduction in enzymatic activity. Replacement
of Lys4 with Arg greatly enhances binding affinity, and a histone
peptide incorporating this mutation has a strong inhibitory
power. Conversely, a peptide bearing a trimethylated Lys4 is
only a weak inhibitor of the enzyme. Rapid kinetics measure-
ments evidence that the enzyme is efficiently reoxidized by
molecular oxygenwith a second-order rate constant of 9.6 103
M1 s1, and that the presence of the reaction product does not
greatly influence the rate of flavin reoxidation. In vivo experi-
ments provide a correlation between the in vitro inhibitory
properties of the tested peptides and their ability of affecting
endogenous LSD1 activity. Our results show that epigenetic
modifications on histone H3 need to be removed before Lys4
demethylation can efficiently occur. The complex formed by
LSD1 with histone deacetylases 1/2 may function as a “double-
blade razor” that first eliminates the acetyl groups from acety-
latedLys residues and then removes themethyl group fromLys4.
We suggest that after H3-K4 demethylation, LSD1 recruits the
forthcoming chromatin remodelers leading to the introduction
of gene repression marks.
Post-translationalmodifications on histone proteins are fun-
damental epigenetic marks that control chromatin state and
gene expression (1, 2), and unraveling epigeneticmechanisms is
a new area of biomedical research (3). Histone lysine demethy-
lases participate in the regulation of chromatin functional
states by removing methyl groups from lysine residues on his-
tone N-terminal tails. At present two different subclasses of
histone lysine demethylases have been identified: the FAD-de-
pendent histone demethylases (4) (Fig. 1) and the JmjC domain
containing histone demethylases, representing iron-dependent
dioxygenases that use 2-oxoglutarate for histone lysine dem-
ethylation via hydroxylation (5). LSD1 was the first discovered
histone demethylase and so far, the only one known to require a
flavin cofactor (4, 6). This enzyme specifically acts on mono-
and dimethylated Lys4 of histone H3 (H3-K4), and its activity
induces gene repression because H3-K4 methylation is gener-
ally associated with activation (7). The enzyme is part of several
multiprotein corepressors including CoREST, CtBP, and a sub-
set of histone deacetylases 1/2 complexes (8–12). The LSD1
catalyzed reaction starts with the oxidation of the H3-K4
N-methyl group carried out by the FAD cofactor (Fig. 1) . The
resulting imine intermediate is then hydrolyzed generating the
demethylated histone and formaldehyde.
We used a combination of in vivo and in vitro experiments in
an effort to characterize LSD1 substrate specificity and mech-
anism of H3-K4 recognition. We provide evidence that oxygen
can be the physiological electron acceptor, and that the enzyme
is likely to function through a ternary complex mechanism. In
addition, our data show that LSD1 can efficiently act only after
removal of the other epigenetic modifications present on the
same histone H3 N-terminal tail.
EXPERIMENTAL PROCEDURES
Protein Preparation and Steady-state Kinetics Measure-
ments—All chemicals were purchased from Sigma unless spec-
ified. HumanLSD1 lacking theN-terminal 157 amino acidswas
expressed and purified as described (6, 13). Enzymatic activities
weremeasured under aerobic conditions by using a peroxidase-
coupled assay (13) on a Cary 100 UV/visible spectrophotome-
ter. Peptides were purchased from Thermo Electron Corpora-
tion. Their purity was greater than 90% as checked by analytical
high pressure liquid chromatography and mass spectrometry.
LSD1 inhibitors were tested by using the peroxidase-coupled
assay in the presence of varied concentrations (2–100 M) of
monomethylated H3-K4 peptide and of the inhibitor under
analysis (global range 1–300 M, depending on the inhibitor
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strength). Initial velocity values were fitted to equations
describing competitive, uncompetitive, and noncompetitive
inhibition patterns using Grafit (Erithacus Software) to obtain
the values of apparent kcat and Km along with their associated
errors. Propagation of statistical error value was carried out as
described (14).
Stopped Flow Kinetics of the Oxidative Half-reaction—
Stopped flow kinetic experiments were performed using a
SX17MV stopped-flow instrument equippedwith a diode array
detector (Applied Photophysics, Leatherhead, UK). For these
experiments, the enzymewas artificially reduced by preparing a
solution of 10 M enzyme in 50 mM HEPES, pH 7.5, also con-
taining benzyl viologen (1.0 M), and xanthine (400 M) in a
total volume of 1.2 ml. After flushing this enzyme solution with
nitrogen, enzyme reduction was initiated by adding 0.2–0.5 nM
xanthine oxidase resulting in full reduction of LSD1 within 30
min. The reduced LSD1 was mixed with buffer (50 mMHEPES,
pH 7.5) with varying oxygen concentrations. Upon mixing in
the stopped-flow instrument, spectral scans were collected
either in 4 or 8ms intervals. The same experiment was repeated
in the presence of 100 M unmodified 21-amino acid histone
H3 peptide. The spectral data were analyzed using the Pro-K
software package (Applied Photophysics).
Cell Line Maintenance and Peptide Transduction—HEK293
cell lines were obtained from the American Type Culture Col-
lection (ATCC) andmaintained in Dulbecco’s modified Eagle’s
medium supplemented with 2 mM glutamax (Invitrogen), 10%
fetal bovine serum, 1% penicillin/streptomycin (Celbio) and
grown in humidified incubators at 37 °C and 5% CO2. HEK293
cells were transduced with selected peptides complexed with
the Chariot reagent (Active Motif, Carlsbad, CA). In brief,
1  106 HEK293 cells/well were seeded in 35-mm culture
plates and incubated until they were at 50% confluence. For
each transduction reaction, 6 l of a 1:10 diluted Chariot
solution was added to 100 l of sterile water, and 500 ng of
peptide was diluted in 100 l of phosphate-buffered saline.
Peptide was added to Chariot dilution and then incubated
for 30 min at room temperature. Cells were overlaid with the
Chariot-peptide complex, and 400 l of serum-free medium
was added to the overlay achieving the final transfection vol-
ume of 600 l. One hour after transfection, 1 ml of complete
growth medium was added to each well without removing
the Chariot-peptide complex. Cells were incubated again at
37 °C in a humidified atmosphere containing 5% CO2 for
1.5 h. In control experiments, cells were treated with the
Chariot reagent without peptide.
Isolation of Total RNA and Real-time Quantitative Reverse
Transcription-PCR Analysis—Total RNA was isolated from
treated or control cells using the RNA WizTM reagent
(Ambion) according to the manufacturer’s protocol. Real-time
PCRs were performed on the iQ5 real-time PCR detection sys-
tem (Bio-Rad) using the iScripTM one-step reverse transcrip-
tion-PCR kit with SYBRGreen. The specificity of the amplifi-
cations was assessed by electrophoretic separation of the
amplified products and melting curve analysis. The expression
of the investigated genes was quantified after normalization
with 2-microglobulin gene (B2M) expression. Primers used
for amplification are the following: B2M forward TGCTGTC-
TCCATGTTTGATGTATCT, B2M reverse TCTCTGCTCC-
CCACCTCTAAGT; -actin forward GGAGAAAATCTGGC-
ACCACACC, -actin reverse GCTGGGGTGTTGAAGGTC-
TCAA; tubulin forward CTCTGTTCGCTCAGGTCCTT-
TTG, tubulin reverse GCCTCCTTCCGTACCACATCC;
SCG10 forward GAAGAAAGACCTGTCCCTG, SCG10
reverse GTTTCAGCACCTGGGCCTCC; SCN1A forward
CATCGCCTGTTGGACAGCTT, SCN1A reverse AGTGGT-
TGTTCCATTGTCATCAG.
Protein Isolation and Western Blotting—Total proteins were
extracted using radioimmune precipitation assay buffer, and
Western blot analysis was carried out using standard tech-
niques. The antibodies used were anti-LSD1 ab17721 (Abcam)
and anti-/-tubulin (Cell Signaling).
RESULTS
Influence of Other Epigenetic Marks on Substrate Recognition
and Enzymatic Activity—Substrate recognition by LSD1 is not
confined to residues neighboring Lys4 but it is achieved through
a network of specific interactions with the 21 N-terminal resi-
dues of histone H3 (4, 13). The histone H3 N-terminal tail has
many potential sites of epigenetic post-translational modifica-
tions, and it was shown that the locus Lys9-Ser10 is particularly
important in affecting LSD1 activity (13). To investigate how
different epigeneticmarks affect the LSD1 demethylation proc-
ess, we tested several 21-amino acid peptides that in addition to
being monomethylated on Lys4 contain other epigenetic cova-
lent modifications (Fig. 2, a and b). For each peptide, we meas-
ured the enzymatic activity with a peroxidase-coupled assay
(Ref. 13 and Table 1), and the resulting steady-state kinetic
FIGURE 1. Histone H3 Lys4 demethylation reaction catalyzed by LSD1. Mono- or dimethylated H3-K4 is oxidized by the FAD cofactor (reductive half-
reaction) to an imine intermediate that is hydrolyzed to yield the demethylated histone tail and formaldehyde. In the oxidative half-reaction, the FAD is
reoxidized by an electron acceptor such as molecular oxygen.
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parameters were evaluated relatively to those obtained with the
21-amino acid monomethylated substrate (peptide 1).
We first tested the effect of arginine methylation, an epige-
netic mark that has been recently shown to be dynamically
modulated (15, 16). Monomethylation of Arg2 (peptide 2)
decreased LSD1 activity by more than 80%, whereas a methyl
group on Arg8 (peptide 3) made the peptide totally unable to
function as a substrate. Arg17monomethylation (peptide 4) had
a lower effect mostly due to a decrease in binding affinity. We
also found that peptide 3 hardly inhibits LSD1 (Ki  100 M)
implying that methylation of Arg8 completely prevents binding
to the enzyme.
Next, we investigated the effect of lysine hyperacetylation, a
post-translational modification of histone H3 that is associated
with gene activation (3). For this purpose, a monomethylated
H3-K4 peptide acetylated at Lys9, Lys14, and Lys18 (peptide 5)
was tested. This peptide did not exhibit any inhibitory or cata-
lytic activity. This observation is in agreement with data
reported by Shi et al. (11) showing that hyperacetylated nucleo-
somes are less susceptible to CoREST/LSD1-mediated dem-
ethylation. Lysine acetylation seems to have an additive effect
because acetylation at Lys9 causes a 6-fold reduction in activity
(13), whereas acetylation of all three Lys residues present in the
21-amino acid peptide leads to complete inactivation. Taken
FIGURE 2. a, sequence of the first 21-amino acids of histone H3 N-terminal tail. This sequence is recognized by LSD1 and is necessary for efficient catalysis.
Arrows indicate the sites of modifications introduced into the 21-amino acid peptides characterized in this study. Residues that have been investigated by
mutagenesis are underlined. b, alteration (percentage) in LSD1 activity for the H3 peptides used in this study. Solid bars indicate the kcat/Km ratio, whereas the
dotted bars refer to the kcat values. For the peptides that are not LSD1 substrates, the inhibition effect was evaluated. Ki values were determined for those
peptides that showed a significant decrease in H3-K4 demethylase activity.Weak inhibition indicates that an inhibitory effect was barely detectable (Ki 100
M). Error bars are shown, and propagation of statistical error value was carried out as described (14).
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together, these experiments demonstrate that Lys4 demethyla-
tion by LSD1 can be drastically reduced by other epigenetic
marks present on the same histone H3 tail.
The Essential Role of Gly12-Gly13 of Histone H3—To investi-
gate whether LSD1 activity is influenced by specific stereo-
chemical and conformational properties of the histone tail, we
inserted point mutations in the H3-K4 monomethylated pep-
tide sequence (Fig. 2, a and b). We designed two peptides, one
with both Gly12 and Gly13 mutated to alanine (peptide 6) and
another with Pro16 replaced by alanine (peptide 7). We chose
glycine and proline as sites for mutagenesis because these
amino acids can either restrain the peptide conformation
(Pro16) or provide the peptide with the conformational flexibil-
ity and/or adaptability required for binding (Gly12-Gly13). Pep-
tide 7 exhibited normal catalytic properties suggesting that the
conformational constraint imposed
by Pro16 ring was not critical for
productive binding to LSD1. Con-
versely, peptide 6 did not function
either as a substrate or as an effec-
tive inhibitor indicating that the
double mutation at Gly12-Gly13
made the peptide unable to bind to
the protein.
Specificity at theH3-K4 Site—The
three-dimensional structure deter-
mination of LSD1 in the substrate-
free state reveals a deep negatively
charged pocket in proximity of the
FAD cofactor and a shallow groove
that might form the substrate-bind-
ing site (17, 18). We explored the
specific properties of the Lys4 bind-
ing site by using a trimethylated
H3-K4 peptide and a peptide bear-
ing an arginine at position 4. In the
former, the charge on Lys4 was
embedded by the three methyl
groups, whereas in the latter the
positive charge was delocalized on
the Arg guanidium group. As
expected, we found that the trim-
ethylatedH3-K4 peptide (peptide 8) is not a substrate for LSD1,
in agreement with the chemical nature of the flavin-dependent
amine oxidation reaction that requires a free lone pair of elec-
trons on the substrate nitrogen atom (19). Furthermore, pep-
tide 8 was found to competitively inhibit LSD1 (Ki, 20 M, Fig.
2b) but to a lower extent compared with the unmodified prod-
uct (Ki, 2 M; Table 1) (13). These data show that the enzyme
senses the presence of the third methyl group so that LSD1 is
both catalytically inactive against trimethylated Lys4 and
unable to bind it with high affinity. In this respect, it is worth-
while to note that LSD1 is much more efficient in discriminat-
ing among H3-K4 methylation states compared with other
chromatin remodeling enzymes (20, 21). The peptide with Lys4
mutated to arginine (peptide 9) was found to be a strong com-
petitive inhibitor of LSD1with ameasuredKi of 0.4M. Among
FIGURE 3.Spectral changesobserveduponmixing10M fully reducedLSD1withbuffer containing1.14
mMO2. Spectra were collected every 4ms; only spectra obtainedwith 20-ms intervals are shown. After decon-
volution, the spectral data couldbe fittedwitha single exponential decay functionyieldinga rateof 5.5 s1. The
inset shows the absorbency at 458 nm as a function of time (black line). The gray line in the inset refers to an
analogous experiment performed in the presence of 100 M inhibitor (peptide 10).
TABLE 1
Kinetic parameters for the H3 peptides (21 amino acids) tested in peroxidase-coupled assay with LSD1
Peptide kcata Kma kcat/Kma Kib
min1 M M1 min1 M
1. Monomethyl Lys4 3.4 0.1 3.4 0.2 1.0 0.1
2. Monomethyl Arg2, monomethyl Lys4 0.63 0.03 5.5 1.4 0.11 0.02
3. Monomethyl Lys4, monomethyl Arg8 No activity No activity No activity Weak
4. Monomethyl Lys4, monomethyl Arg17 2.5 0.2 5.7 1.7 0.43 0.13
5. Monomethyl Lys4, acetyl Lys9, Lys14, Lys18 No activity No activity No activity No inhibition
6. Monomethyl Lys4, mutated G12A, G13A No activity No activity No activity Weak
7. Monomethyl Lys4, mutated P16A 3.0 0.2 4.9 1.2 0.61 0.15
8. Trimethyl Lys4 No activity No activity No activity 19.5 3.2
9. Mutated K4R No activity No activity No activity 0.41 0.05
10. Unmodified peptide (residues 1–21)c No activity No activity No activity 1.8 0.6
11. Shorter unmodified peptide (residues 5–21)c No activity No activity No activity 87 29
a Apparent steady-state kinetic parameters determined as described under “Experimental Procedures.” No activity, the activity is absent or barely detectable.
b Inhibition assays were performed for all the peptides that showed no activity in the peroxidase-coupled assay. The inhibition constant was determined in an assay with peptide
1 as substrate. Values were determined by using competitive inhibition algorithm from the Grafit software package (Erithacus Software). Weak indicates that only a weak
inhibitory effect was detectable (Ki 100 M). Propagation of statistical error value was carried out as described (14).
c Data taken from Forneris et al. (13).
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the many peptides evaluated in this and previous studies (13,
22), peptide 9 exhibits the highest binding affinity and inhibi-
tory power. To exclude that this tight binding simply reflects a
particularly favorable interaction between the delocalized
charge on the guanidinium group and LSD1 active site, we also
probed guanidine, phenyl guanidine, and arginine for potential
LSD1 inhibition. None of these compounds exerted any inhib-
itory effect on LSD1 activity indicating that, although an Arg
side chain at position 4 significantly improved peptide binding,
guanidinium or the isolated arginine amino acid was unable to
bind to LSD1. In a perspective of exploiting chromatin as a
therapeutic target, knowledge on mechanisms of LSD1 inhibi-
tion may help future drug design studies.
Oxygen Reactivity of LSD1—The LSD1-catalyzed demethyla-
tion reaction is an oxidative process that requires an electron
acceptor to reoxidize FAD (Fig. 1). Although it has been shown
that molecular oxygen can function as the electron acceptor
substrate, other molecules were also shown to efficiently reoxi-
dize the LSD1-bound flavin (6). This raises several questions.
Can dioxygen function as physiological electron acceptor?
Does the reduced enzyme react with oxygen when it is still
bound to the demethylated histone? What is the order of the
events during the catalytic cycle? To clarify these issues, we
investigated the kinetics of reduced LSD1with oxygen at pH7.5
and 25 °C by mixing a solution of artificially reduced enzyme
with buffer solutions containing various concentrations of oxy-
gen in the stopped-flow instrument (Fig. 3). A plot of the
pseudo first-order rate constant versus oxygen concentration
was linear (data not shown) giving a bimolecular rate constant
of 9.6  103 M1s1. This value is comparable with the rate
constants typically found in other flavin-dependent oxidases
(23) and indicates that LSD1 can be efficiently reoxidized by
molecular oxygen. These observations suggest that in vivo, the
enzyme likely acts as an oxidase using oxygen as the electron
acceptor required for completion of the catalytic cycle. In addi-
tion, the measured rate constant value indicates that reoxida-
tion by molecular oxygen is a relatively fast process compared
with the turnover numbermeasured in the steady-state kinetics
experiments (13), implying that FAD reoxidation is not rate-
limiting in the demethylation reaction. To dissect the order of
events during the catalytic cycle, we analyzed the kinetics of the
oxygen reaction in the presence of an unmodified histone H3
peptide known to be a LSD1 inhibitor (13) (peptide 10, Table 1).
Addition of such peptide in stopped-flow measurements did
not markedly influence the reoxidation rate (Fig. 3), suggesting
that, after Lys4 demethylation, FAD can be reoxidized by oxy-
gen before release of the demethylated product, i.e. LSD1 is
likely to function through a ternary complex mechanism (23).
This observation has two important implications. First, in the
case of a dimethylated H3-K4 substrate, the twomethyl groups
can be sequentially removed, whereas the protein stays bound
to the histone substrate. Second, after completion of the oxida-
tive demethylation reaction, LSD1 can remain firmly attached
to the histone, functioning as a docking element for the LSD1-
containing corepressor complexes.
In Vivo Assays of LSD1 Inhibition—To further investigate the
ability of LSD1 to bind to a demethylated histone peptide, we
performed an in vivo transduction experiment by delivering
peptides into cells (Fig. 4, a and b). Two peptides were selected
for this experiment: the demethylated peptide consisting of res-
idues 1–21 (peptide 10), which competitively inhibited recom-
binant LSD1 (Table 1); and a shorter unmodified peptide cor-
responding to residues 5–21 (peptide 11), which only weakly
inhibited LSD1 (Ki, 90 M; Table 1) (13). We reasoned that the
presence of an excess of each peptide in HEK293 cells should
compete with the cellular histone H3 tails for the binding to
LSD1. To test the effect of the selected peptides on endogenous
LSD1, we monitored the expression of the SCN1A and SCG10
genes that are targeted by LSD1-containing complexes (4, 24),
compared with the expression levels of three different control
genes, 2-microglobulin (shown in Fig. 4b), -actin, and -tu-
FIGURE 4. Expression levels of LSD1 target genes. a, change in the expres-
sion level of the LSD1-targeted genes SCN1A (dotted bars) and SCG10 (solid
bars) relatively to the housekeeping 2-microglobulin gene expression. The
expression level wasmonitored in the presence of different histoneH3N-ter-
minal tail peptides: the unmodified peptide (peptide 10, Table 1), the shorter
unmodified peptide (peptide 11, Table 1), or without peptide (control). Error
bars represent standard deviation based on two independent experiments,
each one analyzed in triplicate. b, Western blot of total proteins shows
unchanged levels of LSD1 and /-tubulin in HEK293 cells treated with the
above mentioned peptides or without peptide (control).
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bulin. We measured an increase in the expression of both
SCN1A and SCG10 in the presence of peptide 10 (Fig. 4, a and
b), whereas cells treated with peptide 11 (a very weak inhibitor)
displayed no variations in the expression of target genes. These
data are consistent with the notion that H3-K4 methylation is
an activation mark and provides a correlation between the in
vitro inhibitory properties of the peptides and their ability of
affecting the LSD1 activity in vivo.
DISCUSSION
Our results highlight the sophistication and specificity of his-
tone H3 N-terminal tail recognition by LSD1. Within the rec-
ognized segment of 21 amino acids, essential for productive
binding, we found that both post-translational modifications
and conformational properties of the histoneH3 tail are impor-
tant factors in substrate recognition andLys4 demethylation. By
using 21-amino acid peptides in biochemical assays, we previ-
ously demonstrated that phosphorylation on Ser10 drastically
reduces LSD1 enzymatic activity (13). Here we show that
hyperacetylation of Lys residues totally abolishes LSD1 func-
tion, whereas the strength of the effect of Arg methylation
depends on the Arg residue that is modified, varying from a
slight reduction in activity associated to Arg17 methylation to a
complete loss of activity caused by methylation of Arg8. Meth-
ylation of Lys9 appears to be the only epigenetic modification
that does not impair enzyme function (13). Taken together,
these data indicate that epigenetic modifications on the H3 tail
are first removed by other chromatin remodeling enzymes
including histone deacetylases, arginine demethylases, and ser-
ine phosphatases that thereby “prepare” the histone tail for effi-
cient LSD1-catalyzed Lys4 demethylation (Fig. 5). The fact that
LSD1 is typically found in association with histone deacetylases
1/2 is of particular interest in that it suggests that these two
enzymes might function as a sort of “double-blade razor” that
first eliminates the acetyl groups from acetylated Lys residues
and then removes themethyl group fromLys4, effectively prun-
ing the histone H3 N-terminal tail.
The time-resolved stopped-flow experiments demonstrate
that completion of LSD1 catalytic cycle through reoxidation of
the FAD cofactor does not require release of the demethylated
product. In addition, in vivo experiments showed that an
unmodified 21-amino acid peptide (corresponding to the dem-
ethylated product) was able to reactivate target genes by inhib-
iting endogenous LSD1. On these bases we propose that after
demethylating Lys4, LSD1 can remain bound to the histone H3
tail (Fig. 5) possibly tethering other chromatin remodeling
enzymes. In particular, LSD1-containing complexes can
include enzymes that add methyl groups on Lys9, a well known
gene repressionmark on Lys4-demethylated histone (10, 25). In
this view, LSD1may trigger a process that leads to gene repres-
sion acting as a switch between chromatin states. We suggest
that in specific contexts of genes targeted by LSD1-containing
corepressor complexes, H3-K4 demethylation represents the
removal of the last gene activationmark and that LSD1 recruits
the forthcoming chromatin remodelers leading to the intro-
duction of gene repression marks.
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